Vietnam's cancer biomarkers market is experiencing rapid growth as healthcare providers increasingly adopt precision medicine, molecular diagnostics and personalised cancer treatments. Rising cancer incidence, combined with advances in genomic technologies, is accelerating demand for biomarker-based testing across the country's healthcare system.
According to IMARC Group, Vietnam's cancer biomarkers market reached US$138.5 million in 2025 and is projected to grow to US$343.4 million by 2034. The market is being driven by increasing investment in precision oncology, advances in diagnostic technologies and the growing adoption of biomarker-guided treatment strategies.
Cancer biomarkers are measurable biological indicators—such as genetic mutations, proteins and other molecular signatures—that help clinicians detect cancer earlier, predict disease progression and identify the most effective therapies for individual patients. They have become a cornerstone of modern oncology, supporting personalised treatment decisions and improving clinical outcomes.
Several factors are accelerating market growth across Vietnam:
- Rising incidence of breast, lung, colorectal, liver and stomach cancers.
- Increasing adoption of precision medicine and companion diagnostics.
- Expansion of molecular diagnostics and genomic sequencing technologies.
- Growing investment in oncology research and pharmaceutical innovation.
- Government initiatives to strengthen cancer care and expand access to advanced diagnostics.
- Greater use of biomarker testing in clinical trials and targeted drug development.
Vietnam's broader oncology ecosystem is also expanding rapidly. According to IMARC Group, the country's cancer diagnostics market reached US$887.2 million in 2025 and is forecast to grow to US$1.60 billion by 2034, reflecting increasing demand for early detection, molecular testing and advanced diagnostic technologies. At the same time, Vietnam's molecular diagnostics market is expected to grow from US$108.5 million in 2025 to US$175.6 million by 2034, providing a strong foundation for wider adoption of biomarker testing.
Technological innovation is transforming the field of cancer biomarkers. Advances in next-generation sequencing (NGS), liquid biopsy, multi-omics, artificial intelligence and bioinformatics are enabling faster, more accurate identification of clinically relevant biomarkers. These technologies are supporting earlier diagnosis, more precise treatment selection and improved monitoring of treatment response across multiple cancer types.
Demand is particularly strong in breast, lung, colorectal, prostate and gastric cancers, where biomarker-guided therapies have become standard practice in many healthcare systems. Pharmaceutical companies are also increasingly incorporating biomarker testing into clinical trials to identify patients most likely to benefit from targeted therapies and immunotherapies.
Leading global companies including Roche Diagnostics, Thermo Fisher Scientific, QIAGEN, Illumina, Agilent Technologies, Bio-Rad Laboratories, Abbott, Danaher (Cepheid and Beckman Coulter) and Guardant Health continue to expand their oncology diagnostics portfolios, introducing advanced biomarker assays, liquid biopsy platforms and AI-powered genomic analysis tools.
As Vietnam continues to strengthen its oncology services and invest in precision medicine, cancer biomarkers are expected to become an increasingly important component of cancer diagnosis, treatment planning and drug development. For suppliers of molecular diagnostics, genomic technologies, laboratory instrumentation and oncology solutions, Vietnam represents one of Southeast Asia's most promising growth markets.